Nanoform Q2 2023 – A record 11 new customer projects signed and targeting first license/commercial supply agreement in 2024
Company Announcement Nanoform Finland Plc August 24, 2023 08:10 a.m.…
Financial Hearings webcast presentation at 15.00 EEST
https://ir.financialhearings.com/nanoform-q2-2023
Invitation to Nanoform’s Q2 2023 Interim Report
Press release Nanoform Finland Plc August 10, 2023 11:00 a.m.…
Characterization of the Flux Performance of Nanoformed and Untreated Crystalline Piroxicam Solid Suspensions, and the Relative Contributions of the Particle Drifting Effect to In Vitro Flux.
Presented at the 2023 Controlled Release Society Annual Meeting by…
Nanoforming – the Patient- and Planet-Centric Approach From Increasing Bioavailability to Enabling Sustained Drug Delivery.
Nanoforming has emerged as a patient- and planet-centric approach to…